Psyence Biomedical Ltd. filed a report on December 4, 2024, detailing actions taken to meet Nasdaq's equity requirement by securing a $25 million stock purchase agreement and converting debt into shares, successfully raising $3.5 million and achieving stockholders' equity above $2.5 million. The company also acquired a $1.1 million stake in Psyence Labs to enhance its equity position.